Halfway around the world for his mother
In January 2025, Max Doppelt’s mother’s lung cancer had spread to her brain, with around 10 tumours. At a lung cancer conference, a doctor told him that if she lived in China she could simply get a suitable drug, since the country had approved sunvozertinib in 2023.
With the US-China trade war escalating through tariffs and export controls, Doppelt worried that the route to the medicine might soon close. He flew to Shanghai and returned with 26 boxes. He says at least 30 other Americans have made the same trip.
I’m very thankful to all the development that companies in China have done because it saved my mum’s life.
Fifteen months of waiting
The FDA granted sunvozertinib accelerated approval in July 2025. Yet only in July this year did AstraZeneca announce an exclusive licence agreement with Dizal, including a US$600 million upfront payment, up to US$900 million more on regulatory milestones and royalties on global sales.










